Back to results
TerminatedPhase 1

Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-Amyloid Protein Deposition

NCT00968097

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

The Institute for Neurodegenerative Disorders

New Haven, Connecticut, United States

View on ClinicalTrials.gov
Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-Amyloid Protein Deposition — TrialFind